Publicaciones en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (7)

2017

  1. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

    British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413

2016

  1. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

    Journal of Clinical Oncology, Vol. 34, Núm. 32, pp. 3921-3930

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

2014

  1. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

    Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600

2012

  1. IMWG consensus on maintenance therapy in multiple myeloma

    Blood, Vol. 119, Núm. 13, pp. 3003-3015

2009

  1. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 82, Núm. 6, pp. 426-432

  2. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    Blood, Vol. 114, Núm. 9, pp. 1729-1735